Malgorzata B. Gorniak

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.

Journal: Blood advances

Published: June 29, 2026

CD34+ Chimerism and Flow Cytometry Measurable Residual Disease are Independent Predictors of Relapse After Allogeneic Stem Cell Transplantation for AML.

CD34+ Chimerism and Flow Cytometry Measurable Residual Disease are Independent Predictors of Relapse After Allogeneic Stem Cell Transplantation for AML.

Journal: Transplantation and cellular therapy

Published: March 10, 2026

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Journal: Internal medicine journal

Published: November 01, 2025

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

HAT-PCR Enables Sensitive Quantification of Minimal Residual Disease in Chronic Lymphocytic Leukemia and Myeloma.

Journal: International journal of molecular sciences

Published: June 20, 2025

Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma.

Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma.

Journal: Haematologica

Published: May 28, 2024

Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology.

Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology.

Journal: Pathology

Published: January 09, 2024

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice.

The Utility of Euroflow MRD Assessment in Real-World Multiple Myeloma Practice.

Journal: Frontiers in oncology

Published: November 23, 2021

Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.

Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.

Journal: Cytometry. Part B, Clinical cytometry

Published: July 28, 2021

Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.

Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia.

Journal: Cytometry. Part B, Clinical cytometry

Published: June 09, 2021

Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma.

Evaluation of EuroFlow minimal residual disease measurement and donor chimerism monitoring following tandem auto-allogeneic transplantation for multiple myeloma.

Journal: Bone marrow transplantation

Published: July 23, 2020

Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.

Journal: Bone marrow transplantation

Published: October 06, 2016

Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia.

Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia.

Journal: American journal of hematology

Published: July 23, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026